<DOC>
	<DOC>NCT00109252</DOC>
	<brief_summary>This is an open-label, multicenter study designed to evaluate the efficacy and safety of efalizumab administered at weekly SC (subcutaneous) doses of 1.0 mg/kg followed by efalizumab taper in subjects with plaque psoriasis who previously participated in Study ACD2390g.</brief_summary>
	<brief_title>A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed informed consent Previous participation in Study ACD2390g For women of childbearing potential, continued use of an acceptable method of contraception for the duration of their participation in the study Willingness to continue to hold sun exposure reasonably constant and to avoid use of tanning booths or other UV light sources throughout the study Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to efalizumab Systemic therapy for psoriasis (ET Day 0 through FU Day 84 or upon relapse or unusual presentation of psoriasis in the FU period, whichever occurs first) Systemic immunosuppressive drugs for other indications (ET Day 0 through FU Day 84) Topical therapies for psoriasis (ET Day 0 through ET Day 84) Live virus or bacteria vaccines (ET Day 0 through FU Day 84) Other vaccines or allergy desensitization (it is recommended that these be scheduled after FU Day 84) Other experimental drugs or treatments (ET Day 0 through FU Day 84) BetaBlockers, ACE inhibitors, interferons, quinidine, antimalarial drugs, or lithium (if clinically indicated, such medications are allowed but the dosage should be held constant between ET Day 0 and TT Day 84)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Topical</keyword>
</DOC>